These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1657857)

  • 1. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.
    Louie A; Baltch AL; Ritz WJ; Smith RP
    J Antimicrob Chemother; 1991 Jun; 27(6):793-9. PubMed ID: 1657857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
    Ford AS; Baltch AL; Smith RP; Ritz W
    J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.
    Louie A; Baltch AL; Ritz WJ; Smith RP
    Chemotherapy; 1991; 37(4):275-82. PubMed ID: 1665123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of sparfloxacin compared with those of five other quinolones.
    Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
    Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
    J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer.
    Rolston KV; Messer M; Ho DH
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1812-3. PubMed ID: 2285297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis.
    Pastor A; Pemán J; Cantón E
    J Antimicrob Chemother; 1994 Nov; 34(5):679-85. PubMed ID: 7706163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of E-4695, a new fluoro-naphthyridine.
    Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):188-94. PubMed ID: 1327787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
    Giamarellou H; Voutsinas D; Xirouchaki E
    J Chemother; 1992 Feb; 4(1):12-5. PubMed ID: 1328554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between the sensitivity of Pseudomonas aeruginosa and the post-antibiotic effect of sparfloxacin and ciprofloxacin].
    Pastor A; Cantón E; Pemán J
    Rev Esp Quimioter; 1998 Dec; 11(4):333-8. PubMed ID: 9990147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.